Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...
By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavax's Matrix-M adjuvant. The companies have amended ...
Shah Capital frustrated with Novavax's weak COVID-19 vaccine sales Hedge fund increases stake to 8.3%, urges sale to large pharma Novavax's COVID vaccine sales lag behind competitors Nov 13 (Reuters) ...
Hosted on MSN
Why I wouldn't touch Novavax with a 10-foot pole
Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. 10 stocks we like better than Novavax › Novavax (NASDAQ ...
Novavax, Inc.'s valuation remains too high given its reliance on one-off revenues, uncertain royalties, and a complex Sanofi partnership. The company's Q1 2025 earnings were boosted by non-recurring ...
Novavax Inc (NASDAQ:NVAX) shares are trading higher. Reports show a rise in respiratory illnesses across the United States.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results